Survodutide Phase 3 Results Pair Weight Loss with Glycemic Improvements—and a Tolerability Trade-Off

October 1 SYNCHRONIZE2 results report weight and glycemic improvements in adults with type 2 diabetes, while gastrointestinal discontinuations complicate the headline efficacy figures.

For research use only. Not for human consumption.